MA50546A - Compositions et méthodes pour l'internalisation d'enzymes - Google Patents
Compositions et méthodes pour l'internalisation d'enzymesInfo
- Publication number
- MA50546A MA50546A MA050546A MA50546A MA50546A MA 50546 A MA50546 A MA 50546A MA 050546 A MA050546 A MA 050546A MA 50546 A MA50546 A MA 50546A MA 50546 A MA50546 A MA 50546A
- Authority
- MA
- Morocco
- Prior art keywords
- internalization
- enzymes
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762516656P | 2017-06-07 | 2017-06-07 | |
US201762574719P | 2017-10-19 | 2017-10-19 | |
US201862673098P | 2018-05-17 | 2018-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50546A true MA50546A (fr) | 2020-09-16 |
Family
ID=62815133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050546A MA50546A (fr) | 2017-06-07 | 2018-06-06 | Compositions et méthodes pour l'internalisation d'enzymes |
Country Status (16)
Country | Link |
---|---|
US (2) | US11208458B2 (fr) |
EP (1) | EP3635009A1 (fr) |
JP (2) | JP7348844B2 (fr) |
KR (1) | KR20200015932A (fr) |
CN (1) | CN110809583A (fr) |
AU (1) | AU2018281280A1 (fr) |
BR (1) | BR112019025888A2 (fr) |
CA (1) | CA3066569A1 (fr) |
CL (1) | CL2019003586A1 (fr) |
CO (1) | CO2019014682A2 (fr) |
IL (1) | IL271193A (fr) |
MA (1) | MA50546A (fr) |
NZ (1) | NZ760232A (fr) |
PH (1) | PH12019550261A1 (fr) |
TW (1) | TWI820027B (fr) |
WO (1) | WO2018226861A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201709018QA (en) | 2012-03-14 | 2017-11-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
KR20180084895A (ko) * | 2015-12-08 | 2018-07-25 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화 조성물 및 방법 |
RU2020129184A (ru) * | 2018-02-07 | 2022-03-09 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для доставки терапевтического белка |
MX2020012350A (es) * | 2018-05-17 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-cd63, conjugados y usos de estos. |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
CA3108289A1 (fr) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs utilisations pour le traitement de la dystrophie musculaire facio-scapulo-humerale |
JP2021532831A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
US20200157193A1 (en) | 2018-11-21 | 2020-05-21 | Regeneron Pharmaceuticals, Inc. | Anti-staphylococcus antibodies and uses thereof |
SG11202106209RA (en) | 2018-12-19 | 2021-07-29 | Univ Leland Stanford Junior | Bifunctional molecules for lysosomal targeting and related compositions and methods |
JP2022553830A (ja) * | 2019-11-05 | 2022-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | N末端scFv多重特異性結合分子 |
WO2022087484A1 (fr) * | 2020-10-23 | 2022-04-28 | Williams Katherine L | Anticorps contre le coronavirus sars-cov-2 |
KR102494508B1 (ko) * | 2020-12-23 | 2023-02-06 | 아주대학교산학협력단 | CRISPR/Cas 시스템을 이용한 유도만능 줄기세포 제조방법 |
WO2022175532A1 (fr) * | 2021-02-19 | 2022-08-25 | Vib Vzw | Liants de récepteur de mannose-6-phosphate indépendants des cations |
US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
WO2023016828A2 (fr) * | 2021-07-30 | 2023-02-16 | Vib Vzw | Liants du récepteur mannose-6-phosphate indépendants des cations pour la dégradation ciblée de protéines |
WO2023150620A1 (fr) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Insertion de transgène médiée par crispr dans des cellules néonatales |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
CN114731987B (zh) * | 2022-05-19 | 2023-06-23 | 华芯微鱼(苏州)生物科技有限公司 | 颅缝早闭症小鼠模型、其构建方法及应用 |
WO2024026488A2 (fr) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus de récepteur de transférrine modifié |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US5229272A (en) | 1989-04-25 | 1993-07-20 | Igen, Inc. | Catalytic antibody components |
US5156965A (en) | 1983-11-29 | 1992-10-20 | Igen, Inc. | Catalytic antibodies |
US5030717A (en) | 1986-09-17 | 1991-07-09 | Scripps Clinic And Research Foundation | Antibodies which catalyze hydrolysis of ester bonds |
US5126258A (en) | 1984-09-07 | 1992-06-30 | Scripps Clinic And Research Foundation | Molecules with antibody combining sites that exhibit catalytic properties |
AU6942394A (en) | 1993-04-23 | 1994-11-21 | Igen, Inc. | Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies |
US5602021A (en) | 1994-12-29 | 1997-02-11 | Catalytic Antibodies, Inc. | Method for generating proteolytic enzymes specific against a selected peptide sequence |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6261554B1 (en) | 1995-07-25 | 2001-07-17 | Introgene B.V. | Compositions for targeted gene delivery |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5962313A (en) | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
WO1998016254A1 (fr) | 1996-10-17 | 1998-04-23 | Immunomedics, Inc. | Conjugue d'une toxine non antigenique et proteine de fusion d'un systeme recepteur de penetration intracellulaire |
EP0989864A1 (fr) | 1997-06-11 | 2000-04-05 | The School Of Pharmacy, University Of London | Compositions pharmaceutiques contenant des conjugues anticorps-enzymes combines a des promedicaments |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
US6703488B1 (en) | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
US6855804B2 (en) | 1998-03-23 | 2005-02-15 | Board Of Regents, The University Of Texas System | Covalently reactive transition state analogs and methods of use thereof |
DK1068238T3 (da) | 1998-04-02 | 2013-01-14 | Xintela Ab | Integrinheterodimer og subunit deraf |
WO2000022110A2 (fr) | 1998-10-09 | 2000-04-20 | President And Fellows Of Harvard College | Proteolyse ciblee par recrutement de ligases proteiniques d'ubiquitine |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7442777B2 (en) | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7431923B2 (en) | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US20060210474A1 (en) | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
JP2005514429A (ja) | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用薬物のキャリヤーとしての合成無機質ナノ粒子の使用 |
WO2003057179A2 (fr) | 2002-01-11 | 2003-07-17 | Biomarin Pharmaceutical, Inc. | Utilisation de p97 en tant que systeme d'administration d'enzymes en vue d'administrer des enzymes lysosomales therapeutiques |
WO2003092594A2 (fr) | 2002-04-30 | 2003-11-13 | Duke University | Vecteurs viraux et procedes de production et d'utilisation de ceux-ci |
WO2004023973A2 (fr) | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules utilisees a des fins diagnostiques et therapeutiques |
ATE521701T1 (de) | 2003-01-22 | 2011-09-15 | Univ Duke | Verbesserte konstrukte zur expression lysosomaler polypeptide |
SE0301087D0 (sv) | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
SI1620133T1 (sl) | 2003-05-01 | 2016-03-31 | Genzyme Corporation | Genska terapija za nevrometabolne motnje |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
JP2006527590A (ja) | 2003-06-18 | 2006-12-07 | ディレボ・ビオテク・アーゲー | 新規生物学的実体およびその使用 |
US7371539B2 (en) | 2003-12-03 | 2008-05-13 | President And Fellows Of Harvard College | Targeted polypeptide degradation |
JP2007523648A (ja) | 2004-02-06 | 2007-08-23 | バイオマリン ファーマシューティカル インコーポレイテッド | 高リン酸化リソソーム酵素製剤及びそれらの使用 |
WO2005077333A2 (fr) * | 2004-02-10 | 2005-08-25 | University Of Florida Research Foundation, Inc. | Administration sous forme de gel de vecteurs de virus associes aux adenovirus recombines |
CA2553955C (fr) | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Alpha-glucosidase acide et fragments de celle-ci |
US20060171926A1 (en) | 2004-04-30 | 2006-08-03 | Passini Marco A | Gene therapy for neurometabolic disorders |
US7892809B2 (en) | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
WO2006108052A2 (fr) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Ciblage de glycoproteines therapeutiques |
AU2006243776A1 (en) | 2005-05-02 | 2006-11-09 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
EP1904932A4 (fr) | 2005-06-17 | 2013-02-27 | Univ North Carolina | Procedes, systemes et materiaux de fabrication de nanoparticules |
EP4174179A3 (fr) | 2005-08-23 | 2023-09-27 | The Trustees of the University of Pennsylvania | Arn contenant des nucléosides modifiées et leurs procédés d'utilisation |
WO2007143168A2 (fr) | 2006-06-02 | 2007-12-13 | Regeneron Pharmaceuticals, Inc. | Anticorps dirigés contre le récepteur de l'il-6 humaine, à affinité élevée pour ledit récepteur |
US20080089891A1 (en) | 2006-07-26 | 2008-04-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
EP2099523A2 (fr) | 2006-11-13 | 2009-09-16 | ZyStor Therapeutics , Inc. | Méthodes de traitement de la maladie de pompe |
EP2132309A4 (fr) | 2007-02-23 | 2011-01-05 | Univ Florida | Compositions et procédés pour le traitement de maladies liées au stockage du glycogène |
US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
WO2009075815A1 (fr) | 2007-12-07 | 2009-06-18 | Duke University | Thérapie génique d'immunomodulation |
WO2009094561A1 (fr) | 2008-01-24 | 2009-07-30 | The Government Of The United States Of America As Represented By The Secretary Of The Departmentof | Internalisation induite de récepteurs de surface |
AU2009240054B2 (en) * | 2008-04-22 | 2013-08-01 | Life Sciences Research Partners Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
ES2629853T3 (es) | 2008-05-07 | 2017-08-16 | Biomarin Pharmaceutical Inc. | Péptidos de dirección lisosómica y usos de los mismos |
EP2475376B1 (fr) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations pour enzymes lysosomales |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
DK2459231T3 (en) | 2009-07-31 | 2016-09-05 | Ethris Gmbh | RNA with a combination of unmodified and modified nucleotides for protein expression |
WO2011029823A1 (fr) | 2009-09-09 | 2011-03-17 | Novartis Ag | Anticorps monoclonal réactif avec cd63 lors de son expression à la surface de mastocytes dégranulés |
WO2011140279A1 (fr) * | 2010-05-04 | 2011-11-10 | Wayne State University | Ciblage sous-cellulaire faisant intervenir aav de rhodopsines hétérologues dans des cellules ganglionnaires rétiniennes |
US8809282B2 (en) | 2010-05-06 | 2014-08-19 | Duke University | Method of reducing titers of antibodies specific for a therapeutic agent |
WO2012042386A2 (fr) | 2010-09-29 | 2012-04-05 | Oxyrane Uk Limited | Mannosidases capables d'éliminer la coiffe des liaisons mannose-1-phospho- 6-mannose et de démannosyler les n-glycanes phosphorylés, et méthodes facilitant l'assimilation des glycoprotéines par des cellules de mammifères |
US8679478B2 (en) | 2010-10-04 | 2014-03-25 | Duke University | Methods of lysosomal storage disease therapy |
WO2012051220A1 (fr) | 2010-10-11 | 2012-04-19 | Wichita State University | Système de délivrance de médicaments de nanoparticules magnétiques composites |
EP2643468B1 (fr) | 2010-11-22 | 2018-07-04 | Amicus Therapeutics, Inc. | Nouvelles séquences signal pour améliorer les expressions de protéines et la sécrétion d'enzymes recombinées et d'autres protéines |
LT2738259T (lt) | 2011-02-25 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Adam6 pelės |
US9493753B2 (en) | 2011-03-16 | 2016-11-15 | Amano Enzyme Inc. | Modified α-glucosidase and applications of same |
WO2012125987A2 (fr) | 2011-03-17 | 2012-09-20 | Massachusetts Institute Of Technology | Système d'administration |
DK2691529T3 (da) | 2011-03-31 | 2019-09-23 | Univ Iowa Res Found | AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse |
WO2012145644A1 (fr) | 2011-04-22 | 2012-10-26 | Genzyme Corporation | Alpha-glucosidase acide modifiée à traitement accéléré |
US20120283503A1 (en) | 2011-04-29 | 2012-11-08 | The Johns Hopkins University | Nanoparticle loaded stem cells and their use in mri guided hyperthermia |
US9545450B2 (en) | 2011-05-27 | 2017-01-17 | Amicus Therapeutics Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
DK2793567T3 (en) | 2011-12-20 | 2019-04-15 | Regeneron Pharma | Humanized light chain mice |
SG10201709018QA (en) * | 2012-03-14 | 2017-11-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
KR20150020250A (ko) | 2012-06-19 | 2015-02-25 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 당뇨병을 치료하기 위한 조성물 및 방법 |
AU2013289206B2 (en) | 2012-07-11 | 2018-08-09 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
JP2016514096A (ja) * | 2013-02-20 | 2016-05-19 | バレリオン セラピューティクス, エルエルシー | ポンぺ病の処置のための方法および組成物 |
WO2014130722A1 (fr) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Méthodes et compositions pour le traitement de la maladie de forbes-cori |
KR20220119187A (ko) | 2013-05-15 | 2022-08-26 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
WO2014185908A2 (fr) | 2013-05-15 | 2014-11-20 | The Translational Genomics Research Institute | Clones d'hybridomes, anticorps monoclonaux et procédés d'utilisation |
US9388243B2 (en) | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
ES2859605T3 (es) | 2013-07-26 | 2021-10-04 | Univ Iowa Res Found | Procedimientos y composiciones para tratar enfermedades del cerebro |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
EP3800261A1 (fr) | 2014-01-21 | 2021-04-07 | Vrije Universiteit Brussel | Éléments régulateurs d'acides nucléiques spécifiques aux muscles et procédés et leur utilisation |
CA2962081A1 (fr) | 2014-09-26 | 2016-03-31 | Exerkine Corporation | Exosomes utiles pour traiter une maladie de stockage lysosomal |
WO2016065319A1 (fr) | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Ciblage lysosomal d'enzymes et utilisations associées |
MA41022A (fr) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
JP7190352B2 (ja) | 2015-10-23 | 2022-12-15 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 認知保護を提供しつつ疾患の発症及び進行を遅らせるための遺伝子治療を用いた神経変性疾患の治療方法 |
KR20180084895A (ko) | 2015-12-08 | 2018-07-25 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화 조성물 및 방법 |
WO2017117407A1 (fr) | 2015-12-30 | 2017-07-06 | Amicus Therapeutics, Inc. | Alpha-glucosidase acide améliorée pour le traitement de la maladie de pompe |
US20190352423A1 (en) | 2016-02-05 | 2019-11-21 | Genmab A/S | Multispecific antigen-binding molecule with improved internalization characteristics |
SG11201808455VA (en) | 2016-03-30 | 2018-10-30 | Amicus Therapeutics Inc | Formulations comprising recombinant acid alpha-glucosidase |
WO2017191274A2 (fr) | 2016-05-04 | 2017-11-09 | Curevac Ag | Arn codant pour une protéine thérapeutique |
EP3293203A1 (fr) | 2016-09-12 | 2018-03-14 | Genethon | Variants d'alpha-glucosidase acide et leurs utilisations |
CN110050063B (zh) | 2016-09-12 | 2023-11-03 | 吉尼松公司 | 酸性α-葡萄糖苷酶变体及其用途 |
EP3293259A1 (fr) | 2016-09-12 | 2018-03-14 | Genethon | Variants d'alpha-glucosidase acide et leurs utilisations |
CA3041548A1 (fr) | 2016-11-04 | 2018-05-11 | The Children's Hospital Of Philadelphia | Compositions de transfert de gene, methodes et utilisations pour le traitement de maladies neurodegeneratives |
CN109983031B (zh) | 2016-12-26 | 2022-11-25 | Jcr制药股份有限公司 | 通过血脑屏障的新的抗人转铁蛋白受体抗体 |
KR102580320B1 (ko) | 2017-01-27 | 2023-09-19 | 신텔라 에이비 | 골 및 연골 손상 또는 질환의 예방 및 치료 |
IL270530B1 (en) | 2017-05-15 | 2024-03-01 | Amicus Therapeutics Inc | Recombinant human acid alpha-glucosidase |
FI3684423T3 (fi) | 2017-09-20 | 2023-06-15 | 4D Molecular Therapeutics Inc | Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä |
WO2019153009A1 (fr) | 2018-02-05 | 2019-08-08 | Audentes Therapeutics, Inc. | Éléments de régulation de la transcription et utilisations associées |
BR112020013305A2 (pt) | 2018-02-05 | 2021-02-02 | Jcr Pharmaceuticals Co., Ltd. | conjugado de um anticorpo do receptor de transferrina anti-humano e um agente, composições farmacêutica para melhorar uma função muscular, para amenizar disfunções musculares associadas à doença lisossomal, à doença de fabry e à doença de pompe, uso do conjugado, e, método para liberar um agente no músculo |
RU2020129184A (ru) | 2018-02-07 | 2022-03-09 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для доставки терапевтического белка |
KR20210021310A (ko) | 2018-05-16 | 2021-02-25 | 스파크 테라퓨틱스, 인코포레이티드 | 코돈-최적화된 산 알파-글루코시다제 발현 카세트 및 이를 사용하는 방법 |
CN112912399A (zh) | 2018-08-02 | 2021-06-04 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗蓬佩病的用途 |
JP2022513067A (ja) | 2018-11-16 | 2022-02-07 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | ポンペ病を処置するための治療用アデノ随伴ウイルス |
US20220090129A1 (en) | 2018-12-05 | 2022-03-24 | Abeona Therapeutics Inc. | Recombinant adeno-associated viral vector for gene delivery |
-
2018
- 2018-06-06 CN CN201880037686.8A patent/CN110809583A/zh active Pending
- 2018-06-06 CA CA3066569A patent/CA3066569A1/fr active Pending
- 2018-06-06 AU AU2018281280A patent/AU2018281280A1/en active Pending
- 2018-06-06 BR BR112019025888-4A patent/BR112019025888A2/pt unknown
- 2018-06-06 MA MA050546A patent/MA50546A/fr unknown
- 2018-06-06 KR KR1020207000160A patent/KR20200015932A/ko not_active Application Discontinuation
- 2018-06-06 US US16/001,717 patent/US11208458B2/en active Active
- 2018-06-06 NZ NZ760232A patent/NZ760232A/en unknown
- 2018-06-06 EP EP18737065.5A patent/EP3635009A1/fr active Pending
- 2018-06-06 JP JP2019567722A patent/JP7348844B2/ja active Active
- 2018-06-06 WO PCT/US2018/036306 patent/WO2018226861A1/fr active Application Filing
- 2018-06-07 TW TW107119652A patent/TWI820027B/zh active
-
2019
- 2019-12-03 PH PH12019550261A patent/PH12019550261A1/en unknown
- 2019-12-05 IL IL271193A patent/IL271193A/en unknown
- 2019-12-06 CL CL2019003586A patent/CL2019003586A1/es unknown
- 2019-12-24 CO CONC2019/0014682A patent/CO2019014682A2/es unknown
-
2021
- 2021-11-17 US US17/528,828 patent/US20220195011A1/en active Pending
-
2022
- 2022-06-30 JP JP2022106089A patent/JP2022121630A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018226861A4 (fr) | 2019-01-24 |
RU2019143567A3 (fr) | 2022-02-15 |
US20220195011A1 (en) | 2022-06-23 |
US20180355017A1 (en) | 2018-12-13 |
RU2019143567A (ru) | 2021-07-09 |
JP7348844B2 (ja) | 2023-09-21 |
BR112019025888A2 (pt) | 2020-06-30 |
KR20200015932A (ko) | 2020-02-13 |
CL2019003586A1 (es) | 2020-06-05 |
TWI820027B (zh) | 2023-11-01 |
WO2018226861A1 (fr) | 2018-12-13 |
TW201920678A (zh) | 2019-06-01 |
JP2020523321A (ja) | 2020-08-06 |
US11208458B2 (en) | 2021-12-28 |
AU2018281280A1 (en) | 2020-01-16 |
EP3635009A1 (fr) | 2020-04-15 |
CA3066569A1 (fr) | 2018-12-13 |
PH12019550261A1 (en) | 2020-07-13 |
CO2019014682A2 (es) | 2020-01-17 |
NZ760232A (en) | 2023-05-26 |
JP2022121630A (ja) | 2022-08-19 |
IL271193A (en) | 2020-01-30 |
CN110809583A (zh) | 2020-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50546A (fr) | Compositions et méthodes pour l'internalisation d'enzymes | |
MA46643A (fr) | Méthodes et compositions pour le mappage d'arn | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA49403A (fr) | Compositions de pde5 et méthodes d'immunothérapie | |
IL278013B1 (en) | Modulators of secondary methyl enzymes, preparations and uses thereof | |
MA50269A (fr) | Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
IL268788A (en) | Preparations and methods for increased gene expression | |
MA50833A (fr) | Compositions et méthodes pour l'édition génique pour l'hémophilie a | |
EP3471778A4 (fr) | Compositions et méthodes pour administrer des agents biomacromoléculaires | |
EP3386536A4 (fr) | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
MA43515A (fr) | Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll | |
KR20180084895A (ko) | 효소 내재화 조성물 및 방법 | |
MA49715A (fr) | Oligomères et conjugués d'oligomères | |
MA43378A (fr) | Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques | |
MA49693A (fr) | Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue | |
MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
HK1254515A1 (zh) | 含有活動精子結構域的蛋白質2和癌症 | |
MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
MA50354A (fr) | Anticorps ciblant le cd137 et leurs méthodes d'utilisation | |
MA43361A (fr) | Composition pour le soin et la protection de cultures | |
IL272060A (en) | Compositions containing cannabinoids and methods of using them | |
MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse |